{"section": [{"title": "Remarks by Chris Schott", "id": 1, "section": [{"id": 2, "text": "Great. Thanks so much. I guess my question was on capital deployment. I think you mentioned in the prepared remarks that if BD doesn't materialize based on the progression of the pipeline, you'd consider repo at some point down the line. So I guess on that front, how are you thinking about the overall business development landscape at this point? And has your preference on -- or, I guess, actionability of kind of larger deals versus Acceleron type tuck-in evolve to dollars we have gone through this year. I know it's obviously a big kind of point of debate on the Merck story. So I just love to hear your kind of latest thinking on kind of BD landscape. And are we getting closer to a point where maybe repo makes sense just given the cash that seems to be kind of accumulating at the company? Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Chris Schott\", \"section_number\": 1, \"uuid\": \"270018ca-c164-4adc-85e1-7b84e8ee9973\", \"speaker_title\": \"Analyst at JP Morgan\"}"}]}, {"title": "Remarks by Robert M. Davis", "id": 3, "section": [{"id": 4, "text": "Yes. Great, Chris. Thanks for the question, and I'll ask Caroline to comment specifically on the share repurchase side of the question.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Robert M. Davis\", \"section_number\": 2, \"uuid\": \"f0f43cd0-ca61-40d3-be46-2bf8b0817afa\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}, {"id": 5, "text": "But just for the BD landscape, we continue to, frankly, see a portfolio of opportunities we are interested in and are continuing to look at. So as we sit here today, our focus, our urgency on business development has not changed. We do see a list of potential places to play. Obviously, we got to bring them through to fruition which we're working to do. That is our priority because we continue to believe the best thing we can do for long-term value creation is to invest in the sustainability of our business, which is investing in the pipeline of the future in both what we do internally and through BD. So that's our priority. And I do see opportunities.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Robert M. Davis\", \"section_number\": 2, \"uuid\": \"f0f43cd0-ca61-40d3-be46-2bf8b0817afa\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}, {"id": 6, "text": "But obviously, we remain committed also to not hold cash. So with that, maybe I'll let Caroline comment specifically on the share repurchase.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Robert M. Davis\", \"section_number\": 2, \"uuid\": \"f0f43cd0-ca61-40d3-be46-2bf8b0817afa\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Caroline Litchfield", "id": 7, "section": [{"id": 8, "text": "So Chris, our capital allocation priorities are unchanged. We seek to provide a competitive return to our shareholders through both the dividend that we pay and we expect will grow, as well as through share repurchases, while we balance the need to invest in our business in driving growth, as well as in our business development strategies, as Robert just outlined..", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Caroline Litchfield\", \"section_number\": 3, \"uuid\": \"041a4f65-bf85-425c-98a4-0b4613e2a80d\", \"speaker_title\": \"Executive Vice President and Chief Financial Officer at Merck & Co., Inc.\"}"}, {"id": 9, "text": "Given where we are, with our focus on business development, our desire to not create excess cash on the balance sheet, we will look opportunistically at share buybacks based on our assessment of that BD pipeline.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Caroline Litchfield\", \"section_number\": 3, \"uuid\": \"041a4f65-bf85-425c-98a4-0b4613e2a80d\", \"speaker_title\": \"Executive Vice President and Chief Financial Officer at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 10, "section": [{"id": 11, "text": "Great. Thank you, Chris. Next question, please Leo.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 4, \"uuid\": \"c35d2d19-1272-4d3e-80e5-ce3fc5a13cd0\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Daina Graybosch", "id": 12, "section": [{"id": 13, "text": "Yes. I wonder if you could talk a little bit more about your novel pneumococcal vaccine strategy, V116 and V117 and how you think that will compete ultimately with competitor vaccines that continue to increase in their serotype vaccine?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Daina Graybosch\", \"section_number\": 6, \"uuid\": \"7b8a01fc-6b0c-4c69-9000-3d629282f066\", \"speaker_title\": \"Analyst at SVB Securities\"}"}]}, {"title": "Remarks by Dean Y. Li", "id": 14, "section": [{"id": 15, "text": ".This is Dean, I'll take that, and thank you very much for the question. So the top line is, I would just emphasize that our view is that more serotype is not always better and one size does not fit all. Our view, and the view that I've had when I practice medicine, it's the right medicine or, in this case, the right vaccine for the right patient at the right time.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Dean Y. Li\", \"section_number\": 7, \"uuid\": \"ca106c4b-2b42-41f7-b77c-32165e993f40\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 16, "text": "So when you look at VAXNEUVANCE, which is our 15 valent, which has current responses for serotype 3, but also 22F and 33F. If you look at that and you have to look at the epidemiology of pneumococcal disease, it's a bimodal curve where really in the first two years of life, especially in the first year of life, is really important. And then in the adult section, you realize that there's increasing at 45, 55, 65. So there's a bimodal curve.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Dean Y. Li\", \"section_number\": 7, \"uuid\": \"ca106c4b-2b42-41f7-b77c-32165e993f40\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 17, "text": "If you also lay down the different serotypes, the serotypes are quite different between the two. So that's why we believe it's the right vaccine for the right patient at the right time.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Dean Y. Li\", \"section_number\": 7, \"uuid\": \"ca106c4b-2b42-41f7-b77c-32165e993f40\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 18, "text": "Now we have a pediatric V114 that has ACIP that's gone through. And in terms of differentiation and relationship to pediatrics, we don't have clear view of other vaccines, but we are very confident in our ability to give coverage in the first year. And data to date might suggest that, that is an important differentiation in a pediatric study.", "metadata_json": "{\"paragraph_number\": 4, \"speaker\": \"Dean Y. Li\", \"section_number\": 7, \"uuid\": \"ca106c4b-2b42-41f7-b77c-32165e993f40\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 19, "text": "There is some questions in relationship to top line serotype that's been sort of laid out. There's been some discussion of sickness serotype 2 substantial, we can't really comment on that differentiation until we know exactly what serotypes and what the real detailed data.", "metadata_json": "{\"paragraph_number\": 5, \"speaker\": \"Dean Y. Li\", \"section_number\": 7, \"uuid\": \"ca106c4b-2b42-41f7-b77c-32165e993f40\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 20, "text": "In relationship to the adult market, this gives us great insight and great enthusiasm for V116, our 21-valent vaccine. Now that one is specifically targeted for the serotypes that are important for the adult. So it's 21-valent, but I would just emphasize that 11 serotypes in the 21 valent for V116 is not shared by PCV20. And the reason is that we're focused on the adult disease, and we are targeting 85% of residual invasive pneumococcal disease. And I would -- if I look at the vaccines that are in Phase 3, but also Phase 2 or Phase 1 with recent data, I don't know that anyone else has a vaccine that's targeting 85% of the residual invasive pneumococcal disease.", "metadata_json": "{\"paragraph_number\": 6, \"speaker\": \"Dean Y. Li\", \"section_number\": 7, \"uuid\": \"ca106c4b-2b42-41f7-b77c-32165e993f40\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 21, "text": "So more is not better. One size does not fit all the right vaccine, the right patient at the right time.", "metadata_json": "{\"paragraph_number\": 7, \"speaker\": \"Dean Y. Li\", \"section_number\": 7, \"uuid\": \"ca106c4b-2b42-41f7-b77c-32165e993f40\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 22, "section": [{"id": 23, "text": "Thank you, Diana. Next question, please Leo.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 8, \"uuid\": \"01ef61a2-d111-4802-91ed-fb7bf04dabff\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Colin Bristow", "id": 24, "section": [{"id": 25, "text": "Hey good morning. And congrats on the results. A great quarter for GARDASIL, but you talks about the sort of the onetime impact of CDC purchase timing. Can you just quantify the level of impact that had? And then I just wanted to touch base on the additional supply coming online in '23 and '24 and '25. Is this still on track? And could you just specify where the supply is coming from geographically? Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Colin Bristow\", \"section_number\": 10, \"uuid\": \"0132c45d-3791-4b23-96a7-ffebdade61bb\", \"speaker_title\": \"Analyst at UBS\"}"}]}, {"title": "Remarks by Caroline Litchfield", "id": 26, "section": [{"id": 27, "text": "This is Caroline. I'll take a shot at answering your question. So GARDASIL still continues to be a very strong growth driver for our company and will be long into the future given to date only 9% of the world's eligible population are vaccinated. In terms of the quarter results, we saw growth in the U. S., which was largely driven by the CDC timing.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Caroline Litchfield\", \"section_number\": 11, \"uuid\": \"e4f24826-d061-4cac-95f5-4471b3a73200\", \"speaker_title\": \"Executive Vice President and Chief Financial Officer at Merck & Co., Inc.\"}"}, {"id": 28, "text": "In the third quarter of 2021, there was an approximate $125 million buy-in by the CDC. In the third quarter of '22, there was an approximate buy-in of $250 million. So year-over-year, that contributed to growth to the tune of approximately $120 million plus. We do expect the majority of that buy-in by the CDC in the third quarter to come out during the fourth quarter.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Caroline Litchfield\", \"section_number\": 11, \"uuid\": \"e4f24826-d061-4cac-95f5-4471b3a73200\", \"speaker_title\": \"Executive Vice President and Chief Financial Officer at Merck & Co., Inc.\"}"}, {"id": 29, "text": "As we look at our opportunity to satisfy the global demand and protect as many lives as we can going forward we will be supported by the increased supply and capacity that we have coming online commencing 2023. And we expect that, that additional supply will come online over the course of '23, '24 and '25. And therefore, we remain very confident in our ability to protect more lives, to drive growth long into the future, including doubling the revenue of GARDASIL in the year 2030 compared to where we were in 2021.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Caroline Litchfield\", \"section_number\": 11, \"uuid\": \"e4f24826-d061-4cac-95f5-4471b3a73200\", \"speaker_title\": \"Executive Vice President and Chief Financial Officer at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 30, "section": [{"id": 31, "text": "Great. Thank you, Colin. Next question please Leo.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 12, \"uuid\": \"660c3b3d-15e5-44b0-99d4-cc1f9d47b192\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Seamus Fernandez", "id": 32, "section": [{"id": 33, "text": "Well, thanks so much for the question. So I really wanted to ask a question on sotatercept and perhaps the endpoints that surprised you the most. The feedback that we're getting from thought leaders is that the benefit on clinical worsening actually coming as early as it did was a genuine surprise and suggests upside. Just wondering, Dean, where you fit in that point of discussion and perhaps what you're looking forward to in some of the earlier-stage clinical studies for sotatercept? Thanks.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Seamus Fernandez\", \"section_number\": 14, \"uuid\": \"8ff2bb32-f85b-4a72-8a91-df5eb01ae718\", \"speaker_title\": \"Analyst at Guggenheim Securities\"}"}]}, {"title": "Remarks by Dean Y. Li", "id": 34, "section": [{"id": 35, "text": "Thank you very much for that question. So yes, we gave top line results. We're moving with speed to present those data to regulatory authorities throughout.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Dean Y. Li\", \"section_number\": 15, \"uuid\": \"9b6d55ed-1bc2-449a-b612-d2902e922207\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 36, "text": "But just to step back, I just want to remind, at least myself and every -- and others that we were drawn to the sotatercept mechanism because it was a unique mechanism of action. It's a rebalance active in BMP signaling.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Dean Y. Li\", \"section_number\": 15, \"uuid\": \"9b6d55ed-1bc2-449a-b612-d2902e922207\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 37, "text": "The other mechanisms of action could largely be viewed as sales on [Indecipherable], and we have a very strong program in trying to make the best [Indecipherable] medicine. But the mechanism of action you would expect for sotatercept, you would expect it would potentially reprogram the cellular response and essentially be disease modifying.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Dean Y. Li\", \"section_number\": 15, \"uuid\": \"9b6d55ed-1bc2-449a-b612-d2902e922207\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 38, "text": "We are excited about the results. We know that there was a profound effect on 6-minute walk. But as you emphasized, time to clinical worsening, these multi-components are all really important and they came in clinically meaningful and statistically significant. So we are hopeful that we can potentially reshape the treatment of PAH.", "metadata_json": "{\"paragraph_number\": 4, \"speaker\": \"Dean Y. Li\", \"section_number\": 15, \"uuid\": \"9b6d55ed-1bc2-449a-b612-d2902e922207\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 39, "text": "I would emphasize that we talk about HYPERION, venous and CADENCE. But the level of interest that I have in this program is I would point us off to [Indecipherable], which is the follow-on program. And the reason why that is really important to me is given the results that I see, I very much want the individuals who were on the STELLAR trial have the opportunity to get into [Indecipherable], which is an open-label trial, because the effects that we see that will be reported in a meeting likely in 2023 are ones where we must make sure that those individuals who were recruited to STELLAR have continued access to sotatercept. That's how important we think the results are.", "metadata_json": "{\"paragraph_number\": 5, \"speaker\": \"Dean Y. Li\", \"section_number\": 15, \"uuid\": \"9b6d55ed-1bc2-449a-b612-d2902e922207\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 40, "section": [{"id": 41, "text": "Thank you, Seamus. Next question please Leo.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 16, \"uuid\": \"360087ab-2e6b-4c93-8067-892fb3518327\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Steve Scala", "id": 42, "section": [{"id": 43, "text": "Thank you. Rob, you have been CEO for 16 months, and now you're going to be Chairman. What do you view as your greatest accomplishments during this time? And what have been the greatest disappointments? I think given the comments you made when you took over, we might have expected more to be done more quickly to build the pipeline, especially since Merck's pipeline is the second smallest in global pharma. Do you think this is a fair assertion? And if so, why haven't things changed more quickly? Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Steve Scala\", \"section_number\": 18, \"uuid\": \"7a33b4ad-5048-4365-bccd-bded5cdc0d84\", \"speaker_title\": \"A at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Robert M. Davis", "id": 44, "section": [{"id": 45, "text": "Yes. Steve, thanks for the question. Obviously, it's been a fast six months -- or 16 months in the role. But I'd say what I'm most proud of, several things. One, the way the organization has come together as one team and really brought more focus in the business. Obviously, the spin-off of Organon, I think, was very successful, has given us more simple structures, more focus that I feel very good about.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Robert M. Davis\", \"section_number\": 19, \"uuid\": \"c594699c-64d2-49c1-b212-edaa0da0a406\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}, {"id": 46, "text": "Our progress on business development, obviously, the fact that we moved so quickly with Acceleron and then you heard what are just really exceptional results coming out of the STELLAR study, very feel very proud about.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Robert M. Davis\", \"section_number\": 19, \"uuid\": \"c594699c-64d2-49c1-b212-edaa0da0a406\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}, {"id": 47, "text": "But I would say also just overall the way our team has continued to just execute really flawlessly, scientifically, operational, commercially, I couldn't be prouder of what everyone is doing. We've come together and we're really delivering. For all of those things I would say I'm very proud about.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Robert M. Davis\", \"section_number\": 19, \"uuid\": \"c594699c-64d2-49c1-b212-edaa0da0a406\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}, {"id": 48, "text": "On the pipeline itself, I actually think we're making a lot of progress. The fact that a year ago won't even give us credit for having a cardiovascular pipeline. And today, we talk about the fact that by the '24 to '28 time frame, we could be having as many as eight new approvals driving revenue that could be in excess of $10 billion by the mid-2030s across the whole suite of assets, some developed internally and obviously some brought into business development, like what we did with Acceleron. So I feel very good about that.", "metadata_json": "{\"paragraph_number\": 4, \"speaker\": \"Robert M. Davis\", \"section_number\": 19, \"uuid\": \"c594699c-64d2-49c1-b212-edaa0da0a406\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}, {"id": 49, "text": "The progress we're making in vaccines, what we're seeing. I think VAXNEUVANCE is underappreciated. There's a notion that Dean made out of really having a bespoke approach where we were able to cover more of the serotypes that cause disease, whether it be in infants, and then selectively and differently, those in adults. We think that's a real game changer.", "metadata_json": "{\"paragraph_number\": 5, \"speaker\": \"Robert M. Davis\", \"section_number\": 19, \"uuid\": \"c594699c-64d2-49c1-b212-edaa0da0a406\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}, {"id": 50, "text": "Our growing pipeline in neuroscience and immunology, I could go on and on, and the strength that we're continuing to have in adding to our oncology pipeline. So do I think we have everything we need? No. But do I think we've made great progress in a year? I actually think we have, and it gives me confidence that we're going to continue to drive progress. The fact that we did three important business development deals this quarter alone, spanning mRNA technologies, into circular RNA technologies, personalized cancer vaccines and then more traditional oncology agents with a really novel mechanism, those all are adding to the future promise we have in this company. So I actually feel very good about that. More to do, but confidence in what we've done so far.", "metadata_json": "{\"paragraph_number\": 6, \"speaker\": \"Robert M. Davis\", \"section_number\": 19, \"uuid\": \"c594699c-64d2-49c1-b212-edaa0da0a406\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 51, "section": [{"id": 52, "text": "Thanks, Steve. Next question, please Leo.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 20, \"uuid\": \"202fb817-f9d3-4f8a-b4d5-9e2d7d20613b\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Mara Goldstein", "id": 53, "section": [{"id": 54, "text": "Great. Thanks so much for the question. I wanted to ask about the cardiovascular business actually since it was just mentioned. And given the pending applications for sotatercept, where you feel that, that organization from a commercial perspective needs to go. Or are you rightsized to be able to launch and maximize sotatercept in the near term?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Mara Goldstein\", \"section_number\": 22, \"uuid\": \"5ebe64c6-a000-4f3d-9e0f-23b178745107\", \"speaker_title\": \"Analyst at Mizuho Securities\"}"}]}, {"title": "Remarks by Robert M. Davis", "id": 55, "section": [{"id": 56, "text": "Yes. Maybe I can start that and Caroline or Dean can add on. If you look -- if you go back in history, Merck has actually had a strong history and legacy in cardiovascular. And a lot of the -- if you will, the muscle memory still exists in our organization. So I'm very confident that we have what it takes.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Robert M. Davis\", \"section_number\": 23, \"uuid\": \"a88f21ce-a765-45bf-a0ae-c1e865978802\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}, {"id": 57, "text": "But more importantly, we are already out there right now in PAH. We have Adempas. We have [Indecipherable ]. So we have people calling on these doctors. Recall what drove us to think about Acceleron was what we saw in our pipeline, but also what we saw commercially through that experience. So we do have the capabilities.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Robert M. Davis\", \"section_number\": 23, \"uuid\": \"a88f21ce-a765-45bf-a0ae-c1e865978802\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}, {"id": 58, "text": "And also the other thing I'd point out is this is a little different than the way we used to think about the world. This is -- in many cases, a lot of these drugs are still specialty drugs. They're not necessarily the true, traditional, primary care drugs of what we've seen in the past. And I think we're very well positioned. So I have no worries about our confidence and ability to deliver this commercially. We've done it in the past, and we'll do it again.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Robert M. Davis\", \"section_number\": 23, \"uuid\": \"a88f21ce-a765-45bf-a0ae-c1e865978802\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 59, "section": [{"id": 60, "text": "Great. Thank you, Mara. Next question please.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 24, \"uuid\": \"32583d3b-43ef-49e6-8e7b-789b43bf5ff3\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Umer Raffat", "id": 61, "section": [{"id": 62, "text": "Thanks for taking my question. I wanted to touch up on oncology trials, 2 in particular. There's an ongoing subcu KEYTRUDA trial versus IV. I just -- I was curious to gauge your confidence in that and if it's reasonable to assume that vast majority of the franchise that gets switched to subcu. And also this KEYTRUDA plus KRASG12C trial, curious if the early experience implies such a combination is feasible or not? Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Umer Raffat\", \"section_number\": 26, \"uuid\": \"232ababa-448c-47b8-98d9-82260a97800b\", \"speaker_title\": \"Analyst at Evercore ISI\"}"}]}, {"title": "Remarks by Dean Y. Li", "id": 63, "section": [{"id": 64, "text": "I'll take a shot in both of those questions. I'll just emphasize that there is a continuing move to early cancer throughout the field, but especially at Merck. We've talked about the approval that we have in the early stage, both for Lynparza and KEYTRUDA. And this recent Merck-Moderna collaboration is to extend that. It's essentially an IO-IO combination, initially in melanoma, but with the possibility to expand, deepen and extend throughout other tumor types in different stages.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Dean Y. Li\", \"section_number\": 27, \"uuid\": \"3cc16a4f-c733-4ad1-bae2-40b046e29286\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 65, "text": "So given that, the critical thing for patients, especially in the early stage, is to be able to have really excellent access to our medicines, and there is a need for scientific innovation. That is why we're advancing the subcu program. And we are confident that, that will not only be important and successful, but it will be really critical as we move into early phase because the ability cannot be linked to an infusion center of being quite. So we are confident in our strategy of moving into early phase, and it is linked. Each scientific innovation required to improve access.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Dean Y. Li\", \"section_number\": 27, \"uuid\": \"3cc16a4f-c733-4ad1-bae2-40b046e29286\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 66, "text": "In relationship with the RAS program, I have said previously that the RAS program of all of those who are advancing will require a combination. And the ability to move those programs such that you can heavy dose and an ability to combine with other medicines is important. We have early data with our RAF inhibitor and many of the attributes that we think are required for that. We are big that the cards are looking like they they could positively reflect on our KRAS program.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Dean Y. Li\", \"section_number\": 27, \"uuid\": \"3cc16a4f-c733-4ad1-bae2-40b046e29286\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 67, "text": "But we'll share that data, both in monotherapy and in combination with pembrolizumab, at an appropriate time when we present that at a congress.", "metadata_json": "{\"paragraph_number\": 4, \"speaker\": \"Dean Y. Li\", \"section_number\": 27, \"uuid\": \"3cc16a4f-c733-4ad1-bae2-40b046e29286\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Robert M. Davis", "id": 68, "section": [{"id": 69, "text": "And Umer, to the specific question of the conversion, it's probably too early to get into the specifics of that. But I would say, generally, we do see this as bringing meaningful patient benefit. If you think about quality of life, as you move especially in the earlier stages of cancer, to be able to deliver the drug subcutaneously, w think is both innovative and will bring real value to the patients. So that is part of the strategy as we look at the totality of how is it that we continue to deliver for patients as we extend our franchise. So that's something we're looking at, but more details as we get further down the road.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Robert M. Davis\", \"section_number\": 28, \"uuid\": \"225daa5b-e168-45b1-bd74-40d4e3784f32\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 70, "section": [{"id": 71, "text": "Thanks, Umer. Next question, please.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 29, \"uuid\": \"f12867c7-0f10-40db-b3b9-c69fd7c53683\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Mohit Bansal", "id": 72, "section": [{"id": 73, "text": "Great. Thanks for taking my question. And staying on sotatercept, especially with the CADENCE study. So we spoke to a doctor and he was very excited about the study given that there are no approved therapies in the subset of patients you are going after. Could you help us frame expectations for this study? Because a lot of these endpoints are very similar to STELLAR. So would you expect a similar level of efficacy or bar could be lower given there's no standard of care there?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Mohit Bansal\", \"section_number\": 31, \"uuid\": \"65506599-5341-49de-a05d-32898aecf959\", \"speaker_title\": \"Analyst at Wells Fargo\"}"}]}, {"title": "Remarks by Dean Y. Li", "id": 74, "section": [{"id": 75, "text": "Yes. So let me just speak to, we look at both our both sotatercept, and I would just also emphasize our inhaled [Indecipherable] the same sort of general sense, which is we're willing to drive it into PAH. But when you look at the mechanism of action, you ask yourself, is there other places that you can affect diseases, that aren't pulmonary arterial hypertension, but diseases where you have pulmonary hypertension, such as diastolic heart failure or, for example, in lung disease.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Dean Y. Li\", \"section_number\": 32, \"uuid\": \"3fd9d2da-6d4c-4bcb-9432-8bea85a017a6\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 76, "text": "Our expectation is that we want to explore whether sotatercept and its unique mechanism of rebalancing certain molecular pathways could also be applied to those patients who have diastolic heart failure and pulmonary hypertension. And given the impact that sotatercept has that we've seen already with PAH, that gives us a little bit more confidence that that mechanism may be applicable to those people with diastolic heart car failure.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Dean Y. Li\", \"section_number\": 32, \"uuid\": \"3fd9d2da-6d4c-4bcb-9432-8bea85a017a6\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 77, "text": "Equivalent is as we moved our in-house soluble [Indecipherable], in PAH, we're also evaluating whether that molecule could also be used in those patients with lung disease who have pulmonary hypertension. So the results give us more confidence at the next step.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Dean Y. Li\", \"section_number\": 32, \"uuid\": \"3fd9d2da-6d4c-4bcb-9432-8bea85a017a6\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 78, "section": [{"id": 79, "text": "Great. Thank you, Mohit. Next question, please Leo.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 33, \"uuid\": \"64270c45-6796-4118-b8db-6cdaeff0a3a1\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Chris Shibutani", "id": 80, "section": [{"id": 81, "text": "To follow on Steve's question to Rob in terms of the response about what you're most proud about. You talked about the successful implications of spinning off the Organon business and having an organization have a little bit of a simpler structure and focus. I want to juxtapose the question of the Animal Health business. Talk a little bit about your views these days in terms of how that fits the capital allocation priorities, whether you envision potential for that to be a strategic step that you would consider to perhaps separate that business.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Chris Shibutani\", \"section_number\": 35, \"uuid\": \"14f443ff-f5c6-4670-9cd3-31b668108692\", \"speaker_title\": \"Analyst at Goldman Sachs\"}"}]}, {"title": "Remarks by Robert M. Davis", "id": 82, "section": [{"id": 83, "text": "Sure, Chris, thanks for the question. As we've said in the past, we are always looking at the portfolio. We were always asking what is the best structure to develop and generate long-term value for our business and for our shareholders. And with that view, we continue to believe that the Animal Health business is a key growth driver for us. It brings a lot of synergies, frankly, in both directions. Obviously, they are benefiting from their ability to access the science on the human health side. We're benefiting from the value they bring and, in some cases, frankly, on the vaccine side, some of the manufacturing technologies are actually being brought over into the human health side.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Robert M. Davis\", \"section_number\": 36, \"uuid\": \"7695de26-3aeb-4ff1-8f3c-bda5712d8b40\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}, {"id": 84, "text": "So we do see synergies in these 2 businesses. We continue to believe that our ability to invest fully to optimize the opportunity in animal health is there. I think we've demonstrated that to the capital we've deployed and that capital is paying off. And I don't believe that business would have the capital it's had to grow if it wasn't part of Merck. So it's benefiting from what we can bring to them. We're benefiting from what it brings to us and we continue to see it as a strategic asset. So no plans to look at spinning it.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Robert M. Davis\", \"section_number\": 36, \"uuid\": \"7695de26-3aeb-4ff1-8f3c-bda5712d8b40\", \"speaker_title\": \"Chief Executive Officer and President at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 85, "section": [{"id": 86, "text": "Thanks, Chris. Next question, please.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 37, \"uuid\": \"f503ee35-611f-44d5-ac4c-46eff4030af2\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Luisa Hector", "id": 87, "section": [{"id": 88, "text": "Hello, thanks for taking my question. Maybe a little bit more on islatravir, given your confidence to continue development. Can you say any more about the impact the drug is having on lymphocytes at the lower dose? Clearly, you're able to move forward so the regulator is happy. Is there some level of lymphocyte reduction that the regulator will accept? And how should we think about the risk of resistance development with the lower dose? And when might we see some Phase 3 data?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Luisa Hector\", \"section_number\": 39, \"uuid\": \"82c93b30-1791-45bd-b82f-7befd87c4bd2\", \"speaker_title\": \"Analyst at Berenberg\"}"}]}, {"title": "Remarks by Dean Y. Li", "id": 89, "section": [{"id": 90, "text": "Thank you very much for that question. So I just want to emphasize that islatravir is one molecule in our suite of NRTPI molecule. And as you mentioned, we are very interested in the importance of this body of molecules and mechanism, both for the prep setting and for the treatment setting. And it has the possibility of really transforming the longer-acting space.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Dean Y. Li\", \"section_number\": 40, \"uuid\": \"1059a2d6-93e8-4424-add9-a852366c3dc4\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 91, "text": "Specifically to your question, we have a large range of clinical data as...", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Dean Y. Li\", \"section_number\": 40, \"uuid\": \"1059a2d6-93e8-4424-add9-a852366c3dc4\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 92, "section": [{"id": 93, "text": "Excuse me, our conference will continue past 9 a.m.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 42, \"uuid\": \"1d2150c3-3611-4b1c-9979-46d2cd3eb699\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Peter Dannenbaum", "id": 94, "section": [{"id": 95, "text": "We're prepared to go a few extra minutes.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Peter Dannenbaum\", \"section_number\": 44, \"uuid\": \"dcc7caec-af39-43ea-80a9-e96b8b039cfb\", \"speaker_title\": \"Vice President of Investor Relations at Merck & Co., Inc.\"}"}]}, {"title": "Remarks by Dean Y. Li", "id": 96, "section": [{"id": 97, "text": "And so we have a plethora of clinical data. We are very confident that the 0. 25 milligrams will be effective. We are confident that the effects on lymphocytes and CD4 T-cells will be comparable to any standard anti [Indecipherable]. And so that's in the Q day. We're also very interested in moving to the Q week with our partner, Gilead. And hopefully, that will begin to get posted more, but we're focusing on amending the protocol and the dosing regimen under the guidance of the FDA.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Dean Y. Li\", \"section_number\": 45, \"uuid\": \"26bc954f-2b1f-470c-8800-523794b7f4ac\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}, {"id": 98, "text": "And I also want to emphasize that we'll continue to be committed on the 2 month oral. I mean just think, 12 pills a year, 12 pills a year for patients who are high-risk papercraft. We have MK-8527, it is a different molecule in our suite of NRTTI and we're confident.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Dean Y. Li\", \"section_number\": 45, \"uuid\": \"26bc954f-2b1f-470c-8800-523794b7f4ac\", \"speaker_title\": \"Executive vice president and president at Merck & Co., Inc.\"}"}]}], "title": "Q&A for MRK (Merck & Co., Inc.) on 10/27/22 8:00 AM ET", "metadata_json": "{\"company_name\": \"Merck & Co., Inc.\", \"company_ticker\": \"MRK\", \"transcript_date\": \"10/27/22 8:00 AM ET\", \"section_type\": \"Q&A\", \"transcript_url\": \"https://www.marketbeat.com/earnings/transcripts/80115/\"}"}